The Israel Institute for biological research (IIBR), run by the Ministry of defense, has signed a memorandum of understanding with NRx Pharmaceuticals to complete clinical trials of its COVID-19 vaccine.
NRx Pharmaceuticals will send Brilife to phase 3 clinical trials. The testing will be carried out on tens of thousands of volunteers in Georgia, Ukraine and Israel. The pharmaceutical company will then oversee the commercialization of the vaccine.
“As first-generation COVID vaccines increasingly face the challenge of rapidly mutating coronavirus, we are committed to developing a vaccine that can scale quickly and have a low cost price,” said NRx director Haim Hurwitz.
In December, IIBR successfully completed the first phase of testing and began the second phase, which is ongoing.
In June 2020, Israeli biotechnologists announced the successful creation and preclinical trials of the VSV-∆G-spike vaccine (aka BriLife, aka IIBR-10), which consists of the genetically modified Indiana vesicular stomatitis virus (VSV). The latter delivers to the cells the gene encoding the S-protein of the coronavirus, and thereby "training" the immune system takes place.
In April 2021, ambassador to Israel Yevgeny Korniychuk said that the Ukrainian side proposed to conduct the third stage of testing in Ukraine with the subsequent possibility of producing a vaccine, including at our facilities.